申请人:3B Pharmaceuticals GmbH
公开号:EP2954933A1
公开(公告)日:2015-12-16
The present invention is related to a conjugate comprising a structure of general formula (I)
[TM1] - [AD1] - [LM] - [AD2] - [TM2] (I),
wherein
TM1 is a first targeting moiety, wherein the first targeting moiety is capable of binding to a first target,
AD1 is a first adapter moiety or is absent,
LM is a linker moiety or is absent,
AD2 is a second adapter moiety or is absent, and
TM2 is a second targeting moiety, wherein the second targeting moiety is capable of binding to a second target;
wherein the first targeting moiety and/or the second targeting moiety is a compound of formula (II):
wherein
R1 is selected from the group consisting of hydrogen, methyl and cyclopropylmethyl;
AA-COOH is an amino acid selected from the group consisting of 2-amino-2-adamantane carboxylic acid, cyclohexylglycine and 9-amino-bicyclo[3.3.1]nonane-9-carboxylic acid;
R2 is selected from the group consisting of (C1-C6)alkyl, (C3-C8)cycloalkyl, (C3C8)cycloalkylmethyl, halogen, nitro and trifluoromethyl;
ALK is (C2-C5)alkylidene;
R3, R4 and R5 are each and independently selected from the group consisting of hydrogen and (C1-C4)alkyl under the proviso that one of R3, R4 and R5 is of the following formula (III)
wherein
ALK' is (C2-C5)alkylidene;
R6 is selected from the group consisting of hydrogen and (C1-C4)alkyl; and
R7 is a bond;
or a pharmacologically acceptable salt, solvate or hydrate thereof.
本发明涉及一种包含一般式(I)结构的结合物,其中TM1是第一靶向基团,第一靶向基团能够结合到第一个靶标,AD1是第一适配基团或者不存在,LM是连接基团或者不存在,AD2是第二适配基团或者不存在,TM2是第二靶向基团,第二靶向基团能够结合到第二个靶标;其中第一靶向基团和/或第二靶向基团是式(II)化合物之一:其中R1选自氢、甲基和环丙基甲基组成的群;AA-COOH是选自2-氨基-2-环戊烷羧酸、环己基甘氨酸和9-氨基-双环[3.3.1]壬烷-9-羧酸组成的氨基酸;R2选自(C1-C6)烷基、(C3-C8)环烷基、(C3-C8)环烷基甲基、卤素、硝基和三氟甲基的群;ALK是(C2-C5)烷基亚基;R3、R4和R5各自独立地选自氢和(C1-C4)烷基,但是在R3、R4和R5中的一个符合以下式(III):其中ALK'是(C2-C5)烷基亚基;R6选自氢和(C1-C4)烷基;R7是键;或其药理学上可接受的盐、溶剂或水合物。